(MedPage Today) — A once-weekly oral combination of islatravir plus lenacapavir (Sunlenca) for HIV maintained similarly high rates of virologic suppression compared with standard daily oral treatment in an open-label phase II trial.
In 104 virologically…
Source link : https://www.medpagetoday.com/infectiousdisease/hivaids/119149
Author :
Publish date : 2025-12-22 22:42:00
Copyright for syndicated content belongs to the linked Source.
